SCHEMBL4390027

SCHEMBL4390027

OC1OC=Cc2ccccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.38
CYP2D6 P10635 2/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
KDM4E B2RXH2 2/20 0.31
BRD4 O60885 1/20 0.31
CCL2 P13500 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
CHRM2 P08172 1/20 0.31
CYP3A4 P08684 1/20 0.31
CHRM1 P11229 1/20 0.31
DRD2 P14416 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
NFKB1 P19838 1/20 0.31
CHRM3 P20309 1/20 0.31
SLC6A2 P23975 1/20 0.31
HTR2C P28335 1/20 0.31
ADRA1A P35348 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29433715 1.00 HTR2A (0.38) HTR2ACYP2D6MAOAMAOBKDM4E
SCHEMBL4393423 0.82 MAOA (0.33) MAOAMAOB
SCHEMBL9817817 0.77 MAOA (0.38) HTR2ACYP2D6MAOAMAOBMEN1
SCHEMBL2006251 0.74 HTR2A (0.42) HTR2ACYP2D6KDM4EBRD4CCL2
SCHEMBL16398711 0.74 HTR2A (0.38) HTR2ACYP2D6KDM4EBRD4CCL2
SCHEMBL292481 0.74 BRD4 (0.38) HTR2ACYP2D6KDM4EBRD4CCL2
SCHEMBL292479 0.74 HTR2A (0.38) HTR2ACYP2D6KDM4EBRD4CCL2
SCHEMBL28793125 0.74 HTR2A (0.34) HTR2ACYP2D6KDM4EBRD4CCL2
SCHEMBL9934350 0.74 HTR2A (0.38) HTR2ACYP2D6KDM4ELMNATP53
SCHEMBL299075 0.72 EDNRA (0.37) HTR2ACYP2D6BRD4CCL2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1182183-B1 ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICES MADE BY USING THE SAME IDEMITSU KOSAN CO (JP) 2009-12-09 EP claimed
EP-4678189-A2 CANNABINOID COMPOSITIONS AND METHODS OF USING Greenway Herbal Products, LLC (US) 2026-01-14 EP disclosed
US-20200289458-A1 TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN INMED PHARMACEUTICALS INC (CA) 2020-09-17 US disclosed
EP-1182183-B1 ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICES MADE BY USING THE SAME IDEMITSU KOSAN CO (JP) 2009-12-09 EP disclosed
CN-1754877-A Anthracene derivative and electroluminescent device using the same IDEMITSU KOSAN CO (JP) 2006-04-05 CN disclosed
CN-1226250-C Anthracene derivative and electroluminescent device using the same IDEMITSU KOSAN CO (JP) 2005-11-09 CN disclosed
US-6797848-B2 Anthracene derivative and organic electroluminescence device using the derivative IDEMITSU KOSAN, LTD. (JP) 2004-09-28 US disclosed
US-20040100188-A1 Anthracene derivative and organic electroluminescence device using the derivative IDEMITSU KOSAN CO., LTD. (JP) 2004-05-27 US disclosed
CN-1365347-A Anthracene derivative and electroluminescent device using the same IDEMITSU KOSAN CO (JP) 2002-08-21 CN disclosed
US-20020048687-A1 Anthracene derivative and organic electroluminescence device using the derivative IDEMITSU KOSAN CO., LTD. (JP) 2002-04-25 US disclosed
EP-1182183-A1 ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICES MADE BY USING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2002-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040100188-A1 Anthracene derivative and organic electroluminescence device using the derivative ACIN1, KCNQ1, LBR HTR2A 4021/4885CYP2D6 1152/4885MAOA 1621/4885
US-20200289458-A1 TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN CNR2, CNR1, LCAT HTR2A 2548/4885CYP2D6 1444/4885MAOA 4769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.